Switzerland’s Novartis said today it has acquired an 85 percent stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co. providing Novartis with an expanded presence in the Chinese vaccines market. The move is expected to help Novartis introduce additional Novartis vaccines into the Chinese market.
瑞士的诺华公司今天宣布它已经收购了在中国疫苗公司浙江天元生物药业股份有限公司提供了一个在市场中存在的诺华疫苗扩大百分之85的股份。这一举措将有助于诺华在中国市场引入更多的诺华疫苗。
更多信息...
"We look forward to working with Novartis to build a broader portfolio of novel and high-quality vaccines to help prevent disease in China and globally," said Mr. Ding Xiaohang, who is the founder, Chairman and CEO of Tianyuan and will continue his position while holding a minority stake. "We have already identified several joint development programs that could be implemented in China over the next ten years, with the potential of launching key products responding to unmet medical needs in the mid-term."
“我们期待着与诺华公司合作,建立了一种新型的,高品质的疫苗更广泛的组合,以帮助防止在中国和全球的疾病,先生说:“丁航,谁是创始人,董事长兼首席执行官,并将继续他的天元地位,同时持有少数股权。 “我们已经确定了几个联合开发,可以在中国实施,在未来十年开展与应对在中期满足医疗需求的关键产品的潜力,计划。“
说太早? 作者: interdetect 时间: 2011-3-24 11:41
StephenW 发表于 2011-3-24 10:51
"We look forward to working with Novartis to build a broader portfolio of novel and high-quality v ...